Advertisement
Advertisement
LKFT
Lakefront Biotherapeutics - ADR
28.21
USDSponsored
+0.88
+3.22%
May 13, 15:53 UTC -4
Open
LKFT Earnings Reports
Positive Surprise Ratio
LKFT beat 2 of 2 last estimates.
100%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Lakefront Biotherapeutics - ADR earnings per share and revenue
On May 06, 2026, LKFT reported earnings of 0.22 USD per share (EPS) for Q1 26, beating the estimate of -0.51 USD, resulting in a 142.71% surprise. Revenue reached 6.48 million, compared to an expected 71.23 million, with a -90.90% difference.
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
eXp World Holdings, Inc. Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.03
Surprise
+55.88%
ARKO Petroleum Corp. Class A Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
$0.18
Actual
$0.20
Surprise
+7.07%
Novanta Inc. Tangible Equity Units
Report Date
May 11, 2026 For Q1 26
Estimate
$0.79
Actual
$0.81
Surprise
+2.25%
Swarmer, Inc Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.11
Actual
-$0.28
Surprise
-149.55%
Gladstone Investment Corporation 4.875% Notes due 2028
Report Date
May 12, 2026 For Q4 26
Estimate
$0.21
Actual
$0.20
Surprise
-8.80%
Gladstone Investment Corporation 7.875% Notes due 2030
Report Date
May 12, 2026 For Q4 26
Estimate
$0.21
Actual
$0.20
Surprise
-8.80%
Gladstone Land Corporation 6.00% Series B Cumulative Redeemable Preferred Stock
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.23
Actual
$0.08
Surprise
+134.60%
Emera Incorporated
Report Date
May 08, 2026 For Q1 26
Estimate
$1.15
Actual
$1.37
Surprise
+18.46%
WhiteHorse Finance, Inc. 7.875% Notes due 2028
Report Date
May 07, 2026 For Q1 26
Estimate
$0.28
Actual
$0.25
Surprise
-11.88%
FAQ
What were Lakefront Biotherapeutics - ADR's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Lakefront Biotherapeutics - ADR reported EPS of $0.22, beating estimates by 142.71%, and revenue of $6.48M, -90.9% below expectations.
How did the market react to Lakefront Biotherapeutics - ADR's Q1 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Lakefront Biotherapeutics - ADR expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Lakefront Biotherapeutics - ADR's next earnings report?
Based on --
analysts, Lakefront Biotherapeutics - ADR is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement